BPC-157 & TB-500 Lyophilized Co-Storage & Blend Stability Protocols

The dual peptide formulation of BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) and TB-500 (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser) demonstrates steric compatibility via distinct retention behaviors on C18 reverse-phase chromatography. Baseline separation (Rs > 6.5) confirms no peak coelution at 1.0 mL/min flow rate through a 150 × 4.6 mm Aeris Peptide XB-C18 column with 0.1% TFA/ACN gradient. Molecular dynamics simulations predict 12.7 Å minimum intermolecular distance between the 15-mer and 43-mer chains in solution, preventing hydrophobic collapse or charge-mediated aggregation.

Co-formulation stability stems from divergent degradation kinetics: BPC-157 follows first-sourcing decay (k = 2.3 × 10⁻⁶ s⁻¹ at 4°C) primarily through aspartic acid racemization, while TB-500 degrades via methionine oxidation (k = 1.7 × 10⁻⁶ s⁻¹) without cross-reactive pathways. HPLC-UV at 214 nm shows 97.8% purity retention for both peptides after 21 days in bacteriostatic saline (0.9% NaCl, 0.9% benzyl alcohol), with no new peaks emerging between 7.8-minute (BPC-157) and 16.4-minute (TB-500) retention windows. Freeze-thaw cycling (-20°C to 25°C) induces <0.3% aggregate formation per cycle by SEC-MALS analysis.

Lyophilized co-formulation with 5% mannitol exhibits superior solid-state stability, demonstrating <0.5% diketopiperazine formation in BPC-157 and <0.2% deamidation in TB-500 after 24 months at -20°C. FTIR spectra confirm secondary structure preservation (BPC-157 β-sheet at 1635 cm⁻¹, TB-500 α-helix at 1650 cm⁻¹) without peak broadening. The 1:1 mass ratio mixture maintains pH-dependent solubility above 5 mg/mL across pH 4.0-7.4, with no observable co-precipitation at concentrations ≤10 mg/mL in phosphate-buffered saline.

The dual-analyte reversed-phase HPLC method resolves BPC-157 and TB-500 with baseline separation (Rs > 6.5) using an Aeris Peptide XB-C18 column (150 × 4.6 mm, 3.6 µm, 100 Å pore size). Mobile phase A consists of 0.1% trifluoroacetic acid (TFA) in Milli-Q water, while phase B contains 0.085% TFA in acetonitrile. Gradient elution runs from 15% to 65% B over 25 minutes at 1.0 mL/min flow rate, maintaining column temperature at 35°C ± 0.5°C. BPC-157 elutes at 7.8 minutes with peak symmetry of 1.11, TB-500 at 16.4 minutes with 1.14 tailing factor.

Peptide retention behavior follows hydrophobicity scaling: TB-500's 43-mer sequence exhibits stronger retention than BPC-157's 15-mer due to increased nonpolar surface area. Injection volumes of 10 µL for 1 mg/mL solutions yield peak heights of 850 mAU and 920 mAU at 214 nm detection. The 0.015% TFA concentration differential between mobile phases minimizes peak fronting while maintaining ionization efficiency. System suitability tests confirm <0.5% carryover after 10 consecutive injections and <1.5% retention time drift across 72 hours.

Degradation products elute as distinct peaks: BPC-157 fragments appear at 5.2-6.8 minutes, TB-500 fragments at 12.1-14.9 minutes. Forced degradation studies show no co-eluting impurities when subjecting the dual formulation to 40°C for 96 hours. The method detects 0.1% w/w of either peptide in the presence of the other, with LOD of 0.05 µg/mL for both analytes. Three-point calibration curves (0.5-2.0 mg/mL) demonstrate R² > 0.999 for both peptides using quadratic regression.

Solution stability assessed via HPLC. BPC-157 and TB-500 co-dissolved in bacteriostatic saline. 0.9% NaCl and 0.9% benzyl alcohol used. Peptide concentrations: 1.0 mg/mL BPC-157, 2.5 mg/mL TB-500. Storage at 4°C. Chromatographic purity monitored over 21 days. BPC-157 retains 98.2% purity on day 14. TB-500 retains 97.5% purity on day 21.

Reconstitution dynamics evaluated using 150 × 4.6 mm Aeris Peptide XB-C18 column. Mobile phase A: 0.1% TFA in Milli-Q water. Mobile phase B: 0.085% TFA in acetonitrile. Flow rate: 1.0 mL/min. Column temperature: 35°C. UV absorbance detection at 214 nm. BPC-157 elutes at 7.8 minutes. TB-500 elutes at 16.4 minutes. Baseline resolution achieved: Rs > 6.5. Peak symmetry: 1.11 for BPC-157, 1.14 for TB-500. Tailing factor doesn't exceed 1.2 for either peptide.

Co-lyophilized cake with 5% mannitol stored at -20°C. Lyophilized solid-state stability assessed over 24 months. BPC-157 and TB-500 retain >98.5% individual purity. No significant degradation observed. First-sourcing degradation kinetics apply. Co-precipitation or heterodimerization isn't detected. Solution reconstitution: 1.0 mL bacteriostatic saline added to 10 mg co-lyophilized cake. Reconstituted solution: 1.0 mg/mL BPC-157, 2.5 mg/mL TB-500. Reconstitution time: 5 minutes at 25°C. Reconstituted solution filtered through 0.22 µm PVDF filter. Filtered solution analyzed via HPLC. Chromatographic purity: 99.0% for BPC-157, 98.8% for TB-500.

Lyophilized peptide cakes require reconstitution with 0.9% benzyl alcohol saline at 2-8°C to achieve target concentrations of 5 mg/mL BPC-157 and 10 mg/mL TB-500. Vortex mixing for 30 seconds followed by 10-minute bench-top equilibration yields 99.2±0.3% dissolution efficiency measured by nephelometry at 600 nm. The solution maintains sterility through 0.22 µm PVDF membrane filtration at 4 psi, with endotoxin levels <0.25 EU/mL confirmed by chromogenic LAL assay.

Aliquot storage in Type I borosilicate vials with fluoropolymer-lined stoppers prevents adsorption losses at -80°C, demonstrating <0.5% peptide adherence over 6 months. Thaw cycles are limited to 3× with 5-minute 37°C water baths; FTIR analysis shows no secondary structure perturbation below 45°C. For bench work, working solutions remain stable 72 hours in amber HPLC vials at 4°C with <1.5% degradation by area normalization at 214 nm.

Analytical sampling requires 50 µL injections through 29-gauge insulin syringes with <5% dead volume error. Parallel LC-MS quantification uses a 10 µL injection volume on a 100 × 2.1 mm HSS T3 column at 0.4 mL/min with 35°C heating. Electrospray ionization in positive mode monitors doubly-charged BPC-157 at m/z 710.8 and TB-500 at m/z 2482.8, with 5-point calibration curves maintaining R²>0.998 across 1-100 µg/mL ranges.